Oxypro 20 mg

Product Beschrijving

1. Classification and Chemical Overview

Oxypro 20mg is a licensed oral prolonged-release pharmaceutical preparation containing oxycodonhydrochloride (bioequivalent to reference innovator preparations such as OxyContin, Longtec, and Reltebon). Chemically designated as $(5R,9R,13S,14S)\text{-4,5}\alpha\text{-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride}$, oxycodone is a semi-synthetic thebaine-derived phenanthrene opioid alkaloid. Structurally, it possesses a morphinan core featuring an oxygen bridge across carbons 4 and 5, a methoxy substitution at carbon-3, a tertiary hydroxyl group at carbon-14 (which increases $\mu$-opioid receptor affinity and significantly attenuates peripheral histamine release relative to morphine or codeine), and a ketone function at carbon-6. Its empirical molecular formula as the hydrochloride salt is $\text{C}_{18}\text{H}_{21}\text{NO}_4\cdot\text{HCl}$, with an average molecular weight of $351.82\text{ g/mol}$ (unconjugated base: $315.36\text{ g/mol}$).

Standard solid oral presentations of Oxypro 20mg in the United Kingdom consist of round, biconvex, film-coated prolonged-release tablets (characteristically pink in color, often debossed with “20” or manufacturer identifiers on one face). The prolonged-release matrix employs a hydrophilic or lipophilic polymer-based dissolution retardant system (such as ammonio methacrylate copolymer, hypromellose, or stearyl alcohol) compounded with non-active excipients including lactose monohydrate, povidone, talc, magnesium stearate, macrogol, and titanium dioxide (E171) with authorized iron oxide pigments. This matrix is engineered to meter drug diffusion steadily over a 12-hour dosing interval, preventing the immediate release of the $20\text{ mg}$ payload.

Within the United Kingdom regulatory framework:

• Medicinal Classification: Categorized as a Prescription Only Medicine (POM) governed by the Human Medicines Regulations 2012.

• Controlled Drug Scheduling: Under the Misuse of Drugs Act 1971, oxycodone is scheduled as a Class A controlled substance. Under the Misuse of Drugs Regulations 2001, Oxypro 20mg sits in Schedule 2 (CD POM). Prescriptions are subject to strict statutory controls:

  • Maximum prescription validity of 28 days from the date of signature.

  • Mandatory declaration of the formulation, strength, dosing instructions, and total quantity written in both words and figures.

  • Subject to Safe Custody requirements (must be stored within a locked Controlled Drugs cupboard conforming to BS 2881 standards in community pharmacies and hospital wards) and mandatory record-keeping in the statutory Controlled Drugs Register.

• NHS Formulary Positioning: Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff for specialized Step 3 opioid analgesia.

While formulated at a lower strength than the 80mg variant, an individual Oxypro 20mg tablet remains a potent opioid unit (equivalent to approximately $30\text{ to }40\text{ mg}$ of oral morphine daily). Diversion via unregulated online markets or street distribution presents serious toxicological hazards: crushing, chewing, or dissolving the tablet destroys the sustained-release polymer matrix (dose-dumping), precipitating rapid systemic toxicity. Furthermore, black-market supplies sold as diverted “Oxy 20s” carry severe risks of counterfeit substitution with high-potency synthetic nitazene opioids (e.g., metonitazene, protonitazene) or fentanyl analogues.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of oxycodone is characterized by potent, high-affinity agonism at central and peripheral opioid receptors:

• $\mu$-Opioid (MOP) Receptor Agonism: Oxycodone functions as a pure agonist displaying high intrinsic efficacy and selectivity at human $\mu$-opioid receptors located across the dorsal horn of the spinal cord, periaqueductal gray, thalamus, and cortex:

  • Receptor coupling to inhibitory $G_{\alpha i/o}$ heterotrimeric proteins inhibits adenylyl cyclase, lowering intracellular cyclic adenosine monophosphate (cAMP).

  • Presynaptically, it blocks voltage-gated N-type calcium ($Ca^{2+}$) channels, arresting the vesicular exocytosis of primary nociceptive neurotransmitters (substance P, glutamate, and CGRP).

  • Postsynaptically, it opens G-protein-coupled inwardly rectifying potassium (GIRK) channels. The resulting potassium efflux hyperpolarizes postsynaptic projection neurons, stabilizing resting membrane potentials below the threshold required to fire action potentials.

• Direct Intrinsic Activity vs. Active Metabolites: Unlike codeine, oxycodone does not require metabolic bioactivation to exert clinical analgesia. Intact parent oxycodone mediates approximately $80\%$ of its total central analgesic effect. While CYP2D6 converts a small fraction into oxymorphone (which has an affinity for $\mu$-receptors roughly 10-fold higher than oxycodone), circulating concentrations of oxymorphone remain minimal, meaning clinical pharmacodynamics are driven predominantly by the parent drug.

• Relative Potency and Morphine Equivalence: Oxycodone is a potent Step 3 opioid:

  • Oral oxycodone is approximately 1.5 to 2 times as potent as oral morphine.

  • A single Oxypro 20mg tablet taken twice daily provides analgesic exposure equivalent to $60\text{ to }80\text{ mg}$ of oral morphine sulphate over 24 hours.

• Respiratory and Enteric Depression: Agonism within the pontomedullary respiratory pacemakers (pre-Bötzinger complex) blunts chemoreceptor sensitivity to hypercapnia ($\text{PaCO}_2$) and hypoxia, causing dose-dependent bradypnea. In the gastrointestinal tract, activation of myenteric $\mu$-receptors arrests peristalsis and elevates sphincter tone, universally inducing constipation.

3. Approved UK Clinical Indications and Therapeutic Scope

Oxypro 20mg holds recognized Step 3 opioid indications within the British National Formulary (BNF) and National Institute for Health and Care Excellence (NICE) guidelines:

• Severe Cancer-Related Pain:

  • Indicated for the control of severe chronic pain in malignant disease when non-opioids or weak opioids (Step 2) fail to achieve adequate pain control.

  • Dosed strictly on a 12-hourly schedule (e.g., $20\text{ mg}$ every 12 hours). Breakthrough pain is managed using immediate-release oral oxycodone (e.g., OxyNorm liquid or capsules), calculated at one-sixth to one-tenth of the total 24-hour baseline dose (e.g., $5\text{ mg}$ immediate-release PRN for a $40\text{ mg/day}$ total prolonged-release regimen).

• Severe Non-Malignant Chronic Pain (Specialist-Initiated):

  • Indicated for the management of severe chronic non-malignant pain (e.g., severe osteoarthritic pain, refractory post-surgical pain) only when multi-modal non-opioid strategies have failed.

• Clinical Titration Thresholds:

  • Oxypro 20mg represents a common maintenance or early upward-titration strength for patients already established on lower doses (e.g., transitioning upwards from Oxypro 5mg or 10mg BD, or switching from weak opioids like codeine/tramadol at maximum doses).

  • Caution in Opioid-Naive Patients: While lower-strength tablets (5mg or 10mg) are preferred for initiating Step 3 therapy in non-tolerant individuals, initiating an opioid-naive adult directly onto Oxypro 20mg BD carries a high risk of severe sedation, vomiting, and acute respiratory compromise.

• NICE Guidance on Chronic Non-Cancer Pain (NG193):

  • Routine initiation of opioids is not recommended for primary chronic pain (e.g., fibromyalgia, non-specific spinal pain) due to lack of evidence for long-term functional improvement, high dependence risks, and the danger of opioid-induced hyperalgesia (OIH). Treatment must be guided by clear functional targets, scheduled reviews, and an agreed exit/tapering plan.

In non-prescribed and illicit contexts, Oxypro 20mg is sought for euphoric sedation and somatic detachment. Tampering with the tablet (crushing for insufflation or heating for injection) bypasses the release matrix, dramatically elevating the risk of fatal overdose.

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic performance of Oxypro 20mg depends on intact oral ingestion to maintain its biphasic, sustained-release delivery profile:

Biotransformation Pathways

1. $N$-Demethylation via CYP3A4 (Major Route, $\sim 80\%$): The dominant metabolic pathway converts oxycodone into noroxycodone. Noroxycodone is a weak $\mu$-opioid agonist ($>10\text{-fold}$ less potent than oxycodone) with poor blood-brain barrier penetration, contributing negligibly to analgesia.

2. $O$-Demethylation via CYP2D6 (Minor Route, $\sim 10\%$): Converts oxycodone into oxymorphone, a potent $\mu$-opioid agonist. Although oxymorphone possesses high receptor affinity, its circulating plasma concentrations are low, meaning variations in CYP2D6 metabolizer status do not significantly alter the overall clinical analgesic response.

3. Phase II Conjugation: Unchanged drug and Phase I metabolites undergo glucuronidation via UDP-glucuronosyltransferases into polar glucuronide conjugates for renal excretion.

4. Renal Clearance: Less than $10\%$ is cleared unchanged in urine. In patients with severe renal impairment (eGFR $<30\text{ mL/min/1.73 m}^2$), total drug exposure ($AUC$) increases by $40\text{ to }60\%$, requiring conservative dose titration and extended dosing intervals.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration produces potent analgesia and suppression of pain-associated anxiety. However, widespread $\mu$-opioid receptor engagement across multiple organ systems produces a broad adverse event spectrum:

• Gastrointestinal Disturbances (Very Common, $\ge 1/10$):

  • Constipation: Occurs in up to $80\%$ of treated individuals. Opioid receptor binding in the myenteric plexus inhibits propulsive peristalsis and arrests secretomotor fluid transport. Tolerance does not develop; co-prescribing a prophylactic laxative regimen is clinically mandatory.

  • Nausea and vomiting: Triggered by direct stimulation of the chemoreceptor trigger zone (CTZ) in the area postrema.

  • Xerostomia (dry mouth), dyspepsia, and biliary spasm (constriction of the Sphincter of Oddi).

• Central Nervous System and Neuropsychiatric Toxicity (Common, $1/100$ to $<1/10$):

  • Somnolence, daytime sedation, dizziness, headache, and cognitive clouding.

  • Euphoria or paradoxical restlessness, dysphoria, and confusion (more frequent in elderly patients).

  • Muscle fasciculations, myoclonus, and hyperalgesia (associated with high-dose accumulation).

• Cutaneous Reactions:

  • Pruritus, flushing, and diaphoresis. Oxycodone induces significantly less mast-cell degranulation than morphine, but pruritus remains common due to central $\mu$-receptor mechanisms.

• Severe, Emergent and Life-Threatening Hazards (Overdose & Dependence):

  • Catastrophic Central Respiratory Depression: The primary cause of fatal poisoning. Suppression of the medullary pre-Bötzinger complex produces severe bradypnea ($<8\text{ breaths/min}$), progressive cyanosis, stupor advancing to coma, hypercapnic acidosis, and fatal cardiac arrest.

  • Dose-Dumping Toxicity: If an Oxypro 20mg tablet is chewed, crushed, or dissolved, the entire $20\text{ mg}$ payload is released immediately ($C_{max}$ occurs within 30 to 45 minutes rather than 6 to 8 hours), predisposing opioid-naive or partially tolerant individuals to acute respiratory failure.

  • Synergistic Depressant Collapse: Co-ingestion with alcohol, benzodiazepines, or gabapentinoids (pregabalin, gabapentin) dramatically amplifies medullary depression, causing rapid loss of consciousness, airway compromise, and fatal asphyxiation.

  • Physical Dependence and Acute Opioid Withdrawal: Continuous use beyond 2 to 4 weeks drives neuroadaptation. Abrupt discontinuation precipitates a severe withdrawal syndrome: autonomic hyperactivity (tachycardia, hypertension, diaphoresis), gastrointestinal cramping, diarrhea, piloerection (“cold turkey”), pupil dilation (mydriasis), myalgias, and severe insomnia.

  • Counterfeit Nitazene Poisoning: Black-market tablets sold as “Oxy 20” frequently contain synthetic nitazene opioids (e.g., protonitazene, metonitazene), which exhibit potencies tens to hundreds of times higher than morphine, causing rapid, severe respiratory arrest that requires massive, escalated doses of naloxone.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing, titrating, and monitoring Oxypro 20mg mandates strict adherence to safety exclusions, metabolic drug-interaction screening, and Controlled Drugs governance:

• Contraindications:

  • Severe Respiratory Depression: Absolute contraindication in acute respiratory failure, severe chronic obstructive pulmonary disease (COPD), respiratory arrest, or acute severe asthma.

  • Paralytic Ileus or Obstructive Bowel Disease: Absolute contraindication due to the risk of precipitating toxic megacolon or bowel perforation.

  • Raised Intracranial Pressure (ICP) and Severe Head Injury: Opioid-induced $\text{CO}_2$ retention promotes cerebral vasodilation, dangerously spiking intracranial pressure.

  • Severe Hepatic Cirrhosis (Child-Pugh Class C): Clearance of parent drug is severely blunted, leading to massive, uncontrolled drug accumulation.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy.

  • Pregnancy and Breastfeeding: Avoided during pregnancy unless essential (risks neonatal respiratory depression and neonatal opioid withdrawal syndrome [NOWS]); contraindicated in nursing mothers (oxycodone concentrates in breast milk, causing fatal infant sedation).

• Drug Interactions:

  • Potent Cytochrome P450 3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Ritonavir, Grapefruit Juice): High-Level Hazard. Inhibiting CYP3A4 shuts down the primary clearance pathway of oxycodone, increasing plasma $AUC$ by $100\text{ to }200\%$ and doubling its elimination half-life, transforming a standard dose into a dangerous overdose.

  • CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John’s Wort): Accelerates clearance, dropping plasma oxycodone concentrations by up to $50\text{ to }80\%$, risking acute breakthrough pain crises or opioid withdrawal.

  • Central Nervous System Depressants (Benzodiazepines, Alcohol, Gabapentinoids, Sedating Antihistamines): Highest-Tier Mortality Risk. Concomitant use multiplies the risk of fatal respiratory depression, profound coma, and brain damage.

  • Anticholinergic Agents (e.g., TCAs, Antimuscarinics): Compounded paralytic burden on the bowel, drastically elevating the risk of severe obstipation and paralytic ileus.

• Clinical Precautions and Emergency Overdose Management (“Red Flags”):

  • Administration Mandate:

    • Tablets must be swallowed completely whole. They must never be broken, crushed, chewed, or dissolved, as doing so destroys the sustained-release matrix, resulting in rapid dose-dumping and fatal poisoning.

  • Acute Overdose Resuscitation Protocol: Patients presenting to emergency departments (999/A&E) with the classic opioid triad (respiratory depression $<8\text{ breaths/min}$, pinpoint pupils [miosis], and coma):

    • Airway and Oxygenation: Prioritize airway patency, position in the recovery position, deliver high-flow oxygen, and provide bag-valve-mask or mechanical ventilation immediately.

    • Targeted Naloxone Administration: Administer intravenous naloxone ($400\text{ mcg}$ IV initially, titrating up to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes, up to $10\text{ mg}$ as clinically indicated to restore adequate spontaneous ventilation).

    • Extended Monitoring Window for Prolonged-Release Overdose: Because Oxypro 20mg slowly releases active drug from its matrix over 12 hours, naloxone (which has a short half-life of $30\text{ to }60\text{ minutes}$) will wear off long before the tablet has finished absorbing.

    • Once initial resuscitation is achieved, patients must be observed under continuous intensive care / telemetry monitoring for a minimum of 24 hours (or initiated on a continuous intravenous naloxone infusion) to prevent fatal “re-narcotization.”

  • Laxative Co-Prescribing Mandate: Prescribing standards dictate that all patients initiated on Oxypro 20mg must be concurrently co-prescribed a prophylactic laxative regimen (combining an osmotic agent like macrogol with a stimulant laxative like senna) to prevent severe fecal impaction.

  • Structured Discontinuation Protocols: Oxypro 20mg must never be stopped abruptly in dependent individuals. Doses must be tapered down systematically (e.g., reducing the total daily dose by $10\text{ to }20\%$ every 1 to 2 weeks) under close medical supervision to prevent severe autonomic withdrawal and acute pain flares.

  • Driving Regulations: Under Section 5A of the Road Traffic Act 1988, driving with specified controlled drugs in the blood above statutory limits is an offence. While a statutory medical defense applies when the medicine is taken strictly in accordance with prescription instructions, patients must be warned that driving while impaired remains an offence under Section 4 of the Act.